{"schema":"hottub-news/story/v1","story":"st_gxlyph6yblx23rm3m2eq","title":"Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer","title_en":"Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer","outlets":3,"brief":null,"page":"https://hottub.news/stories/fda-approves-durvalumab-with-enfortumab-vedotin-ejfv-for-muscle-gxlyph6ybl","count":3,"items":[{"id":"n_uhsbqowspqlbg244jqxq","seq":11084316,"kind":"article","title":"Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","url":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","published":"2026-11-14T14:54:00Z","seen":"2026-11-14T14:54:00Z","lang":"en","source":{"id":"2minutemedicine.com","name":"2minutemedicine.com","domain":"2minutemedicine.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["2 Minute Medicine","Reviewed Marc Succi","MD (Harvard Medical School)"],"entities":[{"id":"Q19904005","name":"durvalumab","type":"other"},{"id":"Q19904068","name":"enfortumab vedotin","type":"other"}],"story":"st_gxlyph6yblx23rm3m2eq","category":"health","category_p":0.6000000238418579,"sentiment":"neutral","tone":0.18000000715255737,"political":0.11999999731779099},{"id":"n_vwgso7qfsbcd4fob4rga","seq":10916499,"kind":"article","title":"Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer","url":"https://www.timesargus.com/news/business/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedotin-ejfv/article_f3dcea46-595d-595c-8090-0ad71943ef2d.html","summary":"WILMINGTON, Del.--(BUSINESS WIRE)--Nov 13, 2026--","published":"2026-11-13T23:40:05Z","seen":"2026-11-14T00:14:02Z","lang":"en","country":"US","source":{"id":"kite-timesargus-com-f2ab3d","name":"timesargus.com","domain":"timesargus.com","outlet":{"wikidata":"Q4863287","name":"Barre Montpelier Times Argus","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-timesargus-com-f2ab3d","topics":["vermont"],"authors":["Business Wire"],"story":"st_gxlyph6yblx23rm3m2eq","category":"health","category_p":0.5099999904632568,"sentiment":"neutral","tone":0.12999999523162842,"political":0.18000000715255737},{"id":"n_gxlyph6yblx23rm3m2eq","seq":10829928,"kind":"article","title":"FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer","url":"http://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer","published":"2026-11-13T18:22:19Z","seen":"2026-11-13T19:32:53Z","lang":"en","country":"US","source":{"id":"kite-fda-gov-272311","name":"fda.gov","domain":"fda.gov","outlet":{"wikidata":"Q204711","name":"United States Food and Drug Administration","type":"other","country":"US","designations":["food safety organization","united states federal agency"]}},"via":"kite-fda-gov-272311","topics":["healthcare","usa"],"authors":["FDA"],"story":"st_gxlyph6yblx23rm3m2eq","category":"health","category_p":0.46000000834465027,"sentiment":"neutral","tone":0.1899999976158142,"political":0.1899999976158142}]}